Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 2Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1Breast 1

Conditions

Melanoma 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ispinesib × Dermatologic × Clear all
NCT00095953 2013-05-17

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡